Document is current
Any future updates will be listed below
-
Authors
Bolek, Hatice
Kuzu, Omer Faruk
Sertesen Camoz, Elif
Sim, Saadet
Sekmek, Serhat
Karakas, Hilal
Isık, Selver
Günaltılı, Murat
Akkus, Aysun Fatma
Tural, Deniz
Arslan, Cagatay
Goksu, Sema Sezin
Sever, Ozlem Nuray
Karadurmus, Nuri
Karacin, Cengiz
Sendur, Mehmet Ali Nahit
Yekedüz, Emre
Urun, Yuksel https://orcid.org/0000-0002-9152-9887
-
Funding
Funding for this research was provided by:
Social Science University of Ankara
- License Information
-
More Information
Article History
Received: 31 October 2024
Accepted: 23 November 2024
First Online: 15 January 2025
Declarations
:
: Yüksel Ürün declared research funding (Institutional and personal) from Turkish Oncology Group. Yüksel Ürün has served on the advisory board for Abdi-İbrahim, Astellas, AstraZeneca, Bristol Myers-Squibb, Eczacıbası, Gilead, Janssen, Merck, Novartis, Pfizer, Roche. Yüksel Ürün received honoraria or has served as a consultant for Abdi-İbrahim, Astellas, Bristol Myers-Squibb, Eczacıbasi, Janssen, Merck, Novartis, Pfizer, Roche. All remaining authors have declared no conflicts of interest.
